From Biological Insight to a New Class of Medicines for Hemophilia A: The 2026 Lasker-DeBakey Clinical Medical Research Award.

A bispecific antibody mimicking blood coagulation factor VIII has revolutionized hemophilia A treatment, as recognized by the 2026 Lasker-DeBakey Award.

• Why it matters: Hemophilia A is a life-threatening bleeding disorder caused by factor VIII deficiency, and current treatments have limitations. Developing new therapies that effectively replace or mimic factor VIII can significantly improve patient outcomes.
• What they did: The award-winning team developed a bispecific antibody that replicates the function of factor VIII, representing a novel class of medicines for hemophilia A.
• The result: This innovation offers a transformative approach to hemophilia treatment, potentially improving efficacy and safety for patients with factor VIII deficiency.